CN100522178C - 用于治疗男性和女性性无能的制剂 - Google Patents
用于治疗男性和女性性无能的制剂 Download PDFInfo
- Publication number
- CN100522178C CN100522178C CNB038105292A CN03810529A CN100522178C CN 100522178 C CN100522178 C CN 100522178C CN B038105292 A CNB038105292 A CN B038105292A CN 03810529 A CN03810529 A CN 03810529A CN 100522178 C CN100522178 C CN 100522178C
- Authority
- CN
- China
- Prior art keywords
- extract
- herba epimedii
- arginine
- weight ratio
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 201000001881 impotence Diseases 0.000 title description 3
- 238000009472 formulation Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 37
- 241001521901 Tribulus lanuginosus Species 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 239000002243 precursor Substances 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 13
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 7
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 235000009697 arginine Nutrition 0.000 claims description 5
- 229930003935 flavonoid Natural products 0.000 claims description 5
- 150000002215 flavonoids Chemical class 0.000 claims description 5
- 235000017173 flavonoids Nutrition 0.000 claims description 5
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 claims description 4
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 4
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 claims description 4
- 206010024419 Libido decreased Diseases 0.000 claims description 4
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims description 4
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 4
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 claims description 4
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 claims description 4
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 241000893531 Epimedium koreanum Species 0.000 abstract description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 3
- 235000010434 neohesperidine DC Nutrition 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000001329 FEMA 3811 Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- -1 Hydroxypropyl Chemical group 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Chemical class 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002195 fatty ethers Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000000879 neohesperidine DC Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
包含重量比分别为1.5-3.5∶1-2∶0.1-0.4的刺蒺藜、朝鲜淫羊藿、肉桂的提取物和任选的精氨酸或其生理上等效的酯、盐或前体的药物组合物。本发明的组合物可用于治疗男性和女性性功能障碍。
Description
发明描述
本发明涉及可用于治疗男性和女性性功能障碍的制剂。
性功能障碍相当重要，并且成为密集的生物医学研究努力的主题。根据最新统计，各种形式的性无能问题(***缺乏和***功能障碍)影响着约70％的年龄在50岁左右及以上的人口。各种形式的性无能的程度在严重性上有显著差异，特别是在老年人中，其通常在生理上伴有其它异常例如心脏或肾脏疾病。
目前可用于治疗所述功能障碍，特别是***功能障碍的药物包括激素例如睾酮、血管活性肠肽(VIP)、***素衍生物(PG)和心血管药物例如罂粟碱、苯氧苄胺和酚妥拉明。
然而，由于它们引起的副作用和例如使用罂粟碱和***素E2(PGE2)时需要海绵体内或尿道内注射，因而这些药物中没有一个提供对所述问题的令人满意的、持久的解决办法。
最近开发出了cGMP磷酸二酯酶抑制剂，它们尤其可用于治疗性无能，并且口服有效。这些药物之一，被称为西地那非(WO 94/28902)的，已经上市。
但是，其副作用同样不可忽略，因此仍强烈需要更安全和更有效的治疗方法。
目前正在通过现代药理学对众多的天然来源的产品(主要基于植物，但也包括动物)进行研究，在得自传统药物的适应症的基础上对其经验性使用的可能的科学基础进行评价。
生物化学研究已经证实了和性行为有关的生理过程所涉及的复杂的机制，例如***和******、***润滑、***和性高潮。
介质例如一氧化氮(NO)、cAMP和cGMP信使的代谢所涉及的酶因子、平滑肌细胞膜的肾上腺素能受体、多巴胺能神经递质和PG或其它激素的受体是性无能和其它性功能障碍的药理学治疗的可能的靶点。
显然，对这种特殊的问题提供一个令人满意的解决办法是困难的，部分原因在于除了纯粹的生物化学和生理学方面的问题外，还存在可使患有性功能障碍的患者的临床情况更加复杂的环境和心理因素。
目前已经发现，具有特殊性质的药用植物的提取物以一定的用量比组合，在男性和女性性功能障碍的治疗中可以提供特别令人满意的治疗结果。
具体地讲，本发明涉及药物组合物，其包含：
●重量比分别为1.5-3.5:1-2:0.1-0.4的刺蒺藜(Tribulus Terrestris)、朝鲜淫羊藿(epimedium koreanum)、肉桂(cinnamon cassia)的提取物；和任选的
●精氨酸或其生理上等效的酯、盐或前体和适宜的载体或赋形剂。
刺蒺藜、朝鲜淫羊藿、肉桂的提取物是已知的并且已经为同样的目的而被用于某些类型的传统药物中，但是它们的联合使用是未知的，特别是在按如上规定的具体用量比联合使用时。
具体地讲，已知刺蒺藜提取物可诱导睾酮(负责刺激男女***的激素)的合成；朝鲜淫羊藿提取物富含异戊二烯化的类黄酮，具有通过NO释放介导的扩血管作用，因而该提取物具有对动脉和小动脉的血管舒张活性；肉桂提取物通过作用于愉悦相关性多巴胺受体间接地刺激***。
然而，使用本发明的组合物所获得的治疗效果不能单独根据各提取物的活性来解释；事实上，已令人惊奇地发现：当按不同于上述规定的用量比联用所述提取物时，它们是无活性的，甚至可能使所述障碍加重。因此，性行为的真正增强只可能通过按精确的比例使用各种植物的提取物而获得，其既增强***又增加血液对生殖器官的供应。
刺蒺藜、朝鲜淫羊藿、肉桂提取物的重量比优选为2.5:1.5:0.2。
当使用精氨酸、其盐、酯或前体时，其和植物提取物的用量比在0.5至1.5之间，优选为1。
通过常规技术例如用溶剂或超临界液体萃取而获得前述药用植物的提取物可被用于本发明的目的。
然而，优选使用用预先测定的所述提取物的某种典型成分的含量标准化的提取物：例如，刺蒺藜提取物可以含有约40％的以薯蓣皂苷表示的皂苷；朝鲜淫羊藿提取物优选为类黄酮含量(以ikarin表示)约60％的提取物；肉桂提取物优选含有约70％的肉桂醛。
当制备这些提取物时，植物的各个部分均可使用，尽管它们含有不同浓度的活性成分。
特别地，习惯上使用整个植物制备朝鲜淫羊藿提取物；刺蒺藜提取物优选自植物的地上部分和种子中获得。两种情况中，均优选使用40％的乙醇/水混合物在25至85℃的温度下、优选50℃下进行萃取。
肉桂提取物优选通过在150至300巴、优选为210巴的超临界压力条件下使用二氧化碳自树干皮进行萃取而制备。
蒺藜和淫羊藿提取物可通过用水不混溶的溶剂对浓缩的水提取物进行反萃取而进一步浓缩其活性成分，该萃取分别对类黄酮或皂苷具有充分的选择性。适宜的水不混溶或部分混溶的溶剂优选为乙酸乙酯或正丁醇；干燥后，将所用溶剂浓缩至干或浓缩至少量，用活性成分在其中不溶解的非质子溶剂例如脂肪族醚或脂肪族或芳香族烃稀释。将活性成分在非质子溶剂中沉淀可以除去不想要的惰性物质并浓缩活性成分。
由于萃取***有充分的选择性，肉桂提取物的纯化是不必要的。
本发明还涉及重量比分别为1.5-3.5:1-2:0.1-0.4的刺蒺藜、朝鲜淫羊藿和肉桂的提取物和任选的精氨酸或其生理上等效的酯、盐或前体在制备用于治疗男性和女性性功能障碍、特别是用于治疗性无能、***功能障碍、***障碍、***和性快感缺乏的药物中的用途。
作为植物提取物的替换物，也可使用相应的分离出的活性成分，特别是薯蓣皂苷、ikarin和肉桂醛的组合。所述组合在制备用于治疗性无能、***功能障碍、***障碍、***和性快感缺乏的药物中的用途以及包含所述组合的药物是本发明的另一个目的。
本发明的提取物混合物必须长期服用，而不是在***前即刻服用，尽管在某些个体中在第一次治疗时，在服药30分钟内即产生了反应。
本发明组合物的长期给药不引起任何显著的副作用，耐受良好，并且不改变精密的激素平衡，特别是雄性激素/***平衡，其调节男性和女性的重要生理事件例如男性更年期(andropause)和绝经期。
本发明组合物的适宜的给药形式的实例包括含有100至300mg的单位剂量的刺蒺藜提取物和根据前述重量比确定的单位剂量的其它成分的片剂、软和硬明胶胶囊、栓剂和可饮用制剂。特别优选固态制剂，例如未改变释放特性的片剂或耐胃液的片剂，或可饮用液体形式。
下列实施例用来说明本发明而非限制其范围。
实施例1-包衣片的制备
每片700mg的包衣片包含：
刺蒺藜 250.00mg
朝鲜淫羊藿 150.00mg
肉桂 20.00mg
L-精氨酸 100.00mg
大豆多糖 55.00mg
二氧化硅 14.00mg
硅化微晶纤维素 92.00mg
硬脂酸镁 4.00mg
羟丙基甲基纤维素 6.40mg
滑石 5.20mg
二氧化钛 2.00mg
甘油 0.12mg
聚山梨醇酯80 0.80mg
喹啉 0.43mg
靛蓝 0.05mg
实施例2-硬明胶胶囊的制备
每粒340mg的胶囊包含：
刺蒺藜 125.00mg
朝鲜淫羊藿 75.00mg
肉桂 10.00mg
L-精氨酸 50.00mg
大豆多糖 25.00mg
二氧化硅 7.00mg
硅化微晶纤维素 45.00mg
硬脂酸镁 1.50mg
滑石 1.50mg
实施例3-软明胶胶囊的制备
每粒700mg的软明胶胶囊包含：
刺蒺藜 125.00mg
朝鲜淫羊藿 75.00mg
肉桂 10.00mg
L-精氨酸 50.00mg
大豆卵磷脂 20.00mg
中链甘油三酯 100.00mg
聚山梨醇酯80 10.00mg
豆油 300.00mg
胶态二氧化硅 10.00mg
实施例4-可饮用溶液的制备
每10ml的小瓶包含：
刺蒺藜 250.00mg
朝鲜淫羊藿 150.00mg
肉桂 20.00mg
盐酸L-精氨酸 100.00mg
甘油 3000.00mg
聚山梨醇酯20 800.00mg
丙二醇 1000.00mg
丁磺氨钾 175.00mg
糖精钠 40.00mg
新橙皮苷二氢查耳酮DC(Neohesperidine DC) 2.50mg
矫味剂 300.00mg
山梨酸钾 11.70mg
对羟基苯甲酸甲酯 8.30mg
纯化水 足量至10.00mL
实施例5-可溶性颗粒的制备
每5000mg的小袋包含：
刺蒺藜 250.00mg
朝鲜淫羊藿 150.00mg
肉桂 20.00mg
盐酸L-精氨酸 100.00mg
聚山梨醇酯20 500.00mg
丁磺氨钾 175.00mg
糖精钠 40.00mg
新橙皮苷二氢查耳酮DC 2.50mg
矫味剂 300.00mg
菊粉 1000.00mg
甘露醇 2412.50mg
Claims (6)
1.用于治疗男性和女性性功能障碍的药物组合物，其由(i)重量比分别为1.5-3.5:1-2:0.1-0.4的刺蒺藜、朝鲜淫羊藿、肉桂的提取物；和(ii)任选的精氨酸或其生理上等效的酯、盐或前体；和(iii)适宜的载体或赋形剂组成，其中刺蒺藜提取物含有40％的以薯蓣皂苷表示的皂苷，朝鲜淫羊藿提取物为以ikarin表示的类黄酮含量为60％的提取物，肉桂提取物含有70％的肉桂醛。
2.如权利要求1所述的组合物，其中刺蒺藜、朝鲜淫羊藿和肉桂的提取物的重量比为2.5:1.5:0.2。
3.如权利要求1或2所述的组合物，其含有重量比分别为1.5-3.5:1-2:0.1-0.4:0.5-1.5的刺蒺藜、朝鲜淫羊藿、肉桂的提取物和L-精氨酸或盐酸L-精氨酸。
4.如权利要求3所述的组合物，其中刺蒺藜、朝鲜淫羊藿、肉桂的提取物和L-精氨酸或盐酸L-精氨酸的重量比为2.5:1.5:0.2:1。
5.包含重量比分别为1.5-3.5:1-2:0.1-0.4的刺蒺藜、朝鲜淫羊藿、肉桂的提取物和任选的精氨酸或其生理上等效的酯、盐或前体的组合产品在制备用于治疗男性和女性性功能障碍的药物中的用途，其中刺蒺藜提取物含有40％的以薯蓣皂苷表示的皂苷，朝鲜淫羊藿提取物为以ikarin表示的类黄酮含量为60％的提取物，肉桂提取物含有70％的肉桂醛。
6.如权利要求5所述的用途，用于治疗性无能、***功能障碍、***障碍、***和性高潮缺乏。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2002A000994 | 2002-05-10 | ||
| IT2002MI000994A ITMI20020994A1 (it) | 2002-05-10 | 2002-05-10 | Formulazioni utili nel trattamento dell'impotenza maschile e femminile |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1652807A CN1652807A (zh) | 2005-08-10 |
| CN100522178C true CN100522178C (zh) | 2009-08-05 |
Family
ID=11449870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038105292A Expired - Fee Related CN100522178C (zh) | 2002-05-10 | 2003-05-02 | 用于治疗男性和女性性无能的制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7361370B2 (zh) |
| EP (2) | EP1505997B1 (zh) |
| JP (2) | JP4733385B2 (zh) |
| KR (1) | KR20040102219A (zh) |
| CN (1) | CN100522178C (zh) |
| AT (2) | ATE319467T1 (zh) |
| AU (1) | AU2003232248B8 (zh) |
| CA (1) | CA2485389A1 (zh) |
| DE (2) | DE60317946T2 (zh) |
| DK (2) | DK1505997T3 (zh) |
| ES (2) | ES2297593T3 (zh) |
| HK (1) | HK1076033A1 (zh) |
| IL (2) | IL165122A (zh) |
| IT (1) | ITMI20020994A1 (zh) |
| NO (1) | NO332806B1 (zh) |
| PL (2) | PL205893B1 (zh) |
| PT (2) | PT1652520E (zh) |
| RU (1) | RU2313358C2 (zh) |
| SI (1) | SI1652520T1 (zh) |
| WO (1) | WO2003094944A1 (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100692174B1 (ko) * | 2005-03-25 | 2007-03-09 | 손병국 | 신장활성과 항피로, 강정, 강장, 성기능 개선용 건강기능식품 |
| CN1989990B (zh) * | 2005-12-27 | 2010-09-01 | 郭凯 | 一种治疗***功能障碍的药物及其制备方法 |
| EP2011496A1 (en) * | 2007-07-03 | 2009-01-07 | Indena S.P.A. | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| US9918489B2 (en) * | 2008-12-17 | 2018-03-20 | Mark Gorris | Food-based supplement delivery system |
| US20100178413A1 (en) * | 2008-12-17 | 2010-07-15 | Mark Gorris | Food-based Supplement Delivery System |
| US20110206788A1 (en) | 2010-01-29 | 2011-08-25 | Chaudhary Latha | Novel herbal composition |
| IT1395768B1 (it) * | 2009-09-17 | 2012-10-19 | Iacono | Integratore alimentare con componenti che stimolano la funzione sessuale nel maschio |
| ITRM20100068A1 (it) * | 2010-02-19 | 2011-08-20 | Fabrizio Iacono | Integratore alimentare con componenti che stimolano la funzione sessuale nel maschio |
| ES2430226T3 (es) * | 2009-09-17 | 2013-11-19 | Tradapharma Sagl | Suplemento dietético que estimula la función sexual masculina |
| ES2386859B1 (es) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | Composición natural para aumentar el vigor. |
| RU2458537C1 (ru) * | 2011-03-14 | 2012-08-20 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики эректильной дисфункции у мужчин |
| KR20130032419A (ko) * | 2011-09-23 | 2013-04-02 | 씨제이제일제당 (주) | 복합생약추출물을 포함하는 발기부전 예방 및 개선용 조성물 |
| US9913870B2 (en) * | 2012-01-13 | 2018-03-13 | Dharma Biomedical, Llc | Method for stimulating AMP-activated protein kinase |
| RU2496491C1 (ru) | 2012-08-20 | 2013-10-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ восстановления полового влечения (либидо) у мужчин путем применения биологически активной добавки к пище для восстановления полового влечения (либидо) у мужчин |
| TW201420745A (zh) * | 2012-11-26 | 2014-06-01 | Tian-De Li | 擴充男性海綿體的複方精油 |
| CN103250852A (zh) * | 2013-02-24 | 2013-08-21 | 沈根林 | 一种中药补肾蜜饯肠 |
| CN103250851A (zh) * | 2013-02-24 | 2013-08-21 | 沈根林 | 一种中药补肾蜜饯肠 |
| CN104000198B (zh) * | 2014-06-13 | 2016-03-23 | 上海赫尔伯生物科技有限公司 | 一种具有补肾填精、益神兴阳作用的复方胶囊及其制备方法 |
| CN104352540B (zh) * | 2014-10-20 | 2017-08-18 | 成都中医药大学 | 一种治疗冠心病心绞痛的亲水凝胶骨架型缓释片及其制备方法 |
| WO2017010487A1 (ja) * | 2015-07-13 | 2017-01-19 | 協和発酵バイオ株式会社 | アルギニンを高含有する錠剤 |
| CN106614589A (zh) * | 2016-11-13 | 2017-05-10 | 徐州得铸生物科技有限公司 | 一种含蒺藜皂甙的杀虫剂组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU674602B2 (en) * | 1993-09-14 | 1997-01-02 | Hyung Ki Choi | Pharmaceutical composition for prophylaxis and treatment of premature ejaculation |
| FR2765483B1 (fr) * | 1997-07-04 | 2000-02-04 | Philippe Gorny | Medicament destine a traiter les dysfonctions erectiles |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US20020013280A1 (en) * | 2000-06-16 | 2002-01-31 | Zhongcheng Xin | Pharmaceutical composition for preventing and treating sexual dysfunction and vasculargenic disease comprising icariin |
| KR100394329B1 (ko) * | 1999-06-17 | 2003-08-09 | 북경동방백오의약개발유한공사 | 성기능장애 및 혈관계질환의 치료용 약제학적 조성물 |
| US6702733B1 (en) * | 1999-07-01 | 2004-03-09 | 40 J's Llc | Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds |
| KR20010009653A (ko) | 1999-07-12 | 2001-02-05 | 유제경 | 성기능 장애를 위한 치료용 조성물 |
| US20010008638A1 (en) | 1999-07-14 | 2001-07-19 | Brian J. Wilding | Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form |
| US6343258B1 (en) | 1999-08-13 | 2002-01-29 | ALEXIS Brian | Method for testing for readiness for harvesting of tribulus terrestris l. having high steroidal saponin content |
| US6399579B1 (en) * | 2000-08-15 | 2002-06-04 | Hauser, Inc. | Compositions comprising icariside I and anhydroicaritin and methods for making the same |
| US6803060B2 (en) * | 2000-09-07 | 2004-10-12 | Joe Reyes | Composition to boost libido |
-
2002
- 2002-05-10 IT IT2002MI000994A patent/ITMI20020994A1/it unknown
-
2003
- 2003-05-02 PT PT05025314T patent/PT1652520E/pt unknown
- 2003-05-02 DE DE60317946T patent/DE60317946T2/de not_active Expired - Lifetime
- 2003-05-02 AT AT03749863T patent/ATE319467T1/de active
- 2003-05-02 WO PCT/EP2003/004611 patent/WO2003094944A1/en active IP Right Grant
- 2003-05-02 US US10/513,819 patent/US7361370B2/en not_active Expired - Fee Related
- 2003-05-02 DK DK03749863T patent/DK1505997T3/da active
- 2003-05-02 CN CNB038105292A patent/CN100522178C/zh not_active Expired - Fee Related
- 2003-05-02 RU RU2004133025/15A patent/RU2313358C2/ru not_active IP Right Cessation
- 2003-05-02 JP JP2004503027A patent/JP4733385B2/ja not_active Expired - Fee Related
- 2003-05-02 CA CA002485389A patent/CA2485389A1/en not_active Abandoned
- 2003-05-02 ES ES05025314T patent/ES2297593T3/es not_active Expired - Lifetime
- 2003-05-02 KR KR10-2004-7017938A patent/KR20040102219A/ko active Search and Examination
- 2003-05-02 AT AT05025314T patent/ATE380024T1/de active
- 2003-05-02 EP EP03749863A patent/EP1505997B1/en not_active Expired - Lifetime
- 2003-05-02 PL PL387861A patent/PL205893B1/pl unknown
- 2003-05-02 PT PT03749863T patent/PT1505997E/pt unknown
- 2003-05-02 DE DE60303940T patent/DE60303940T2/de not_active Expired - Lifetime
- 2003-05-02 DK DK05025314T patent/DK1652520T3/da active
- 2003-05-02 ES ES03749863T patent/ES2259144T3/es not_active Expired - Lifetime
- 2003-05-02 SI SI200331079T patent/SI1652520T1/sl unknown
- 2003-05-02 AU AU2003232248A patent/AU2003232248B8/en not_active Ceased
- 2003-05-02 EP EP05025314A patent/EP1652520B1/en not_active Expired - Lifetime
- 2003-05-02 PL PL373096A patent/PL204549B1/pl unknown
-
2004
- 2004-11-09 NO NO20044877A patent/NO332806B1/no not_active IP Right Cessation
- 2004-11-09 IL IL165122A patent/IL165122A/en not_active IP Right Cessation
-
2005
- 2005-09-16 HK HK05108129.2A patent/HK1076033A1/xx not_active IP Right Cessation
-
2008
- 2008-02-25 US US12/036,522 patent/US7438934B2/en not_active Expired - Fee Related
- 2008-06-12 IL IL192137A patent/IL192137A/en not_active IP Right Cessation
-
2010
- 2010-12-02 JP JP2010269123A patent/JP2011079853A/ja active Pending
Non-Patent Citations (2)
| Title |
|---|
| 中药大辞典. 江苏新医学院，892，2251，上海科学技术出版社. 1986 |
| 中药大辞典. 江苏新医学院，892，2251，上海科学技术出版社. 1986 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100522178C (zh) | 用于治疗男性和女性性无能的制剂 | |
| RU2440127C2 (ru) | Лекарственные формы, полезные для лечения мужской и женской импотенции | |
| WO2006002096A2 (en) | Low doses of l-citrulline for treating diseases | |
| NO20120640L (no) | Formuleringer anvendelige til behandling av impotens hos kvinner og menn | |
| PL203555B1 (pl) | Kompozycje farmaceutyczne zawieraj ace ekstrakty Tribulus terrestris, Turnera diffusa, Cinnamon cassia i ekstrakt z Ginkgo biloba oraz ich zastosowanie do wytwarzania leku do leczenia m eskiej i ze nskiej impotencji |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076033 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1076033 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090805 Termination date: 20150502 |
|
| EXPY | Termination of patent right or utility model |